Autologous Transplant in HIV Patients (BMT CTN 0803)

Phase 2 Completed 43 enrolled Medical College of Wisconsin Blood and Marrow Transplant Clinical Trials Network · collab National Cancer Institute (NCI) · collab National Heart, Lung, and Blood Institute (NHLBI) · collab National Marrow Donor Program · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.

Timeline

Start: 2010-04
Primary completion: 2015-05
Completion: 2016-06

Publications

Results Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. doi: 10.1182/blood-2015-08-664706. Epub 2016 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Cytarabine	Small molecule	100 mg/m2	—
Background	Etoposide	Small molecule	100 mg/m2	—
Background	Melphalan	Small molecule	140 mg/m2	—
Background	carmustine	Small molecule	300 mg/m2	—

Autologous Transplant in HIV Patients (BMT CTN 0803)

Summary

Timeline

Publications

Drugs

Indications